Brief: Nicox's NCX 470 Shows Significant Intraocular Pressure Lowering In Dolomites Phase 2 Glaucoma Trial

Nicox SA

01/07/2021 06:32

July 1 (Reuters) - Nicox SA  NCOX.PA :
    * REG-NICOX’S NCX 470 DEMONSTRATES SIGNIFICANT INTRAOCULAR
PRESSURE LOWERING IN DOLOMITES PHASE 2 GLAUCOMA TRIAL
    * PHASE 3 ON TRACK WITH FIRST TRIAL RESULTS EXPECTED IN Q2
2022
    * RESULTS FROM FIRST PHASE 3 TRIAL, MONT BLANC, ARE
CURRENTLY
EXPECTED IN Q2 2022
    * RESULTS FROM SECOND PHASE 3 TRIAL, DENALI, ARE NOW
EXPECTED IN
2023, PREVIOUSLY ANNOUNCED AS Q4 2022
    * NCX 470 IS CURRENTLY IN TWO MULTI-REGIONAL PHASE 3
GLAUCOMA
CLINICAL TRIALS, MONT BLANC AND DENALI

Source text for Eikon:  ID:nGNE3CjHRn 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))